IPCA Laboratories Intrinsic Value
IPCALAB • Healthcare
Current Stock Price
₹1601.20
Primary Intrinsic Value
₹980.32
Market Cap
₹4003 Cr
+100.0%
Upside
Median Value
₹3202.40
Value Range
₹480 - ₹4003
Assessment
Trading Below Calculated Value
Safety Margin
50.0%
IPCALAB Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹980.32 | ₹784.26 - ₹1176.38 | -38.8% | EPS: ₹44.56, Sector P/E: 22x |
| Book Value Method | asset | ₹4003.00 | ₹3602.70 - ₹4403.30 | +150.0% | Book Value/Share: ₹3355.20, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹3202.40 | ₹2882.16 - ₹3522.64 | +100.0% | Revenue/Share: ₹4134.40, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹3202.40 | ₹2882.16 - ₹3522.64 | +100.0% | EBITDA: ₹2060.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹4003.00 | ₹3202.40 - ₹4803.60 | +150.0% | CF Growth: 4.9%, Discount: 15% |
| PEG Ratio Method | growth | ₹480.36 | ₹432.32 - ₹528.40 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹688.45 | ₹619.61 - ₹757.30 | -57.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹3202.40 | ₹2882.16 - ₹3522.64 | +100.0% | ROE: 13.4%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹1834.10 | ₹1650.69 - ₹2017.51 | +14.5% | EPS: ₹44.56, BVPS: ₹3355.20 |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
IPCALAB Intrinsic Value Analysis
What is the intrinsic value of IPCALAB?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of IPCA Laboratories (IPCALAB) is ₹3202.40 (median value). With the current market price of ₹1601.20, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹480.36 to ₹4003.00, indicating ₹480.36 - ₹4003.00.
Is IPCALAB undervalued or overvalued?
Based on our multi-method analysis, IPCA Laboratories (IPCALAB) appears to be trading below calculated value by approximately 100.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 6.05 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 13.4% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 19.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.88x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for IPCA Laboratories
Additional stock information and data for IPCALAB
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹1,321 Cr | ₹886 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹945 Cr | ₹338 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹806 Cr | ₹444 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹856 Cr | ₹431 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹1,090 Cr | ₹830 Cr | Positive Free Cash Flow | 8/10 |